A study testing whether a new weekly shot from Regeneron Pharmaceuticals, olatorepatide, can help with weight.

Who can join

Adults 18 to 65, have obesity or are overweight, BMI 27+.

What you take

olatorepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The study runs about 9 months.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US.

Primary condition: Overweight or Obesity.

Who can join, in detail

Key inclusion criteria

• Body mass index >=27.0 kg/m^2 to <45.0 kg/m^2 at screening
• Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment

Key exclusion criteria

• History of Type 1 or Type 2 diabetes
• Change in body weight >5 kg within approximately 3 months before screening as described in the protocol
• Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, prior to randomization or planned during the study period
• History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years as described in the protocol

Where this study is enrolling

This trial has 3 US sites across 3 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2026-03-16. Expected completion: 2026-12-28. Last updated on ClinicalTrials.gov: 2026-04-29.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact